Regeneron Pharmaceuticals Inc. buy PapaSmurf
Start price
19.10.19
/
50%
€268.00
Target price
19.12.19
-
Performance (%)
25.13%
End price
19.12.19
€335.35
Summary
This prediction ended on 19.12.19 with a price of €335.35. The prediction had a final performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.619% | -3.619% | 4.004% | -14.317% |
| iShares Core DAX® | -3,51 % | -8,75 % | -1,00 % | 48,50 % |
| iShares Nasdaq 100 | -2,78 % | -0,63 % | 14,22 % | 78,81 % |
| iShares Nikkei 225® | -2,04 % | -6,84 % | 24,87 % | 51,56 % |
| iShares S&P 500 | -2,60 % | -2,23 % | 9,20 % | 60,51 % |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy Regeneron Pharmaceuticals Inc.